This article has been archived.
Please use for reference only.
Penn Home Infusion Team
University of Pennsylvania Health System
Last Modified: November 1, 2001
Your doctor has ordered neupogen to increase the number of white blood cells in your body. White blood cells help your body to fight infection.
Subcutaneous injections are given with a 25 gauge needle behind your arms, in your abdomen (away from your navel or waist) or on the top of your thighs. You should record the place where you inject your neupogen because if you use the same site your neupogen will not be effective. REMEMBER TO ROTATE THE SITE OF INJECTION.
You will need the following supplies:
3cc syringe with 25 gauge needle
Vial of neupogen
Record of injection sites
Wash your hands. (See Handwashing section for more details).
Remove neupogen from the refrigerator. Remove cap from neupogen and clean top with alcohol.
Remove the packaging from the syringe.
Pull back the plunger on the syringe to ________________ cc and recap the needle.
Draw up ________________ cc of neupogen.
Remove air bubbles in syringe by gently tapping on the syringe to make the air bubbles rise to the top of the syringe. Gently push the air bubbles out of the syringe by pushing on the plunger.
Warm neupogen by rolling the syringe between your palms. DO NOT SHAKE!
Wipe area to be injected with an alcohol swab.
Firmly hold skin to be injected with thumb and forefingers.
Hold syringe at a 45 degree angle and quickly insert needle into your skin.
With the needle in place in your skin pull back on the plunger to and check for blood. If you do get any blood in the syringe, remove the needle without injecting the neupogen. Restart procedure from beginning.
If you do not get blood return withdrawal blood, slowly inject the neupogen.
After you have injected the neupogen remove needle from your skin and place in the needle box.
Apr 21, 2011 - Subcutaneous bortezomib has non-inferior efficacy and better safety than standard intravenous administration for patients with relapsed multiple myeloma, according to a study published online April 19 in The Lancet Oncology.